Chamomile has been utilized for hundreds of years for insomnia, upset stomach, and inflammation. In recent years, scientific inquiry has grown significantly into its promising anticancer activity. In vitro and in vivo studies have demonstrated that specific bioactive compounds in chamomile—particularly apigenin and luteolin—may inhibit the proliferation of cancer cells in cell cultures. The plant-derived molecules appear to block critical cellular mechanisms that enable cancer cells to divide uncontrollably. One notable finding suggests that apigenin can trigger apoptosis—targeted cell suicide—in cancerous tissue while leaving intact healthy cells. These effects have been recorded in tissue samples of breast, prostate, skin, and digestive tract cancers. It’s crucial to recognize, these findings stem from highly controlled lab settings and may not directly reflect equivalent effects in human patients. Medical trials involving chamomile derivatives in individuals undergoing cancer therapy remain insufficiently extensive. Using chamomile tea or chamomile supplements is considered low-risk for the general population, https://asresalamat.ir/7-properties-of-chamomile-tea-what-is-chamomile-tea-good-for/, published on Help On, they cannot substitute for conventional oncology treatments. Investigations are ongoing to explore whether chamomile compounds could enhance current therapeutic regimens or alleviate therapy-induced complications such as inflammation and cellular damage from free radicals. Higher-quality large-scale human studies are urgently needed to ascertain whether chamomile can contribute meaningfully in cancer prevention or managing malignancies. For now, chamomile remains a compelling candidate for further investigation—but not a validated remedy.